Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (756)	11/27/2001 1:21:46 PM
From: tuck	Read Replies (1) \| Respond to of 2243

Rick, Seems to me that bolded portion is saying they can modulate this ubiquitin ligase (among other things that seem beneficial, but maybe not -- this why you talk of other toxicities and await animal data?), via inhibition by tinkering with different parts of this SLAP-2 molecule. Indeed, I would think animal data is being generated now, next logical step at this point, IMO. I am anticipating this will be positive, but do you see any specific hints about toxicities from any of this so far? Thinking large shareholders may indeed lighten up, and some of them before X-Mas in an expected market pullback. I could see RIGL hitting lower mid 4s. I'll yell then (BLUE HP will be buying) and if I find preclinical stuff. Edit: No tyrosine kinase domain ==> combo therapy possibilities? Like EBIO under $2, but not very T/FIFish. Cheers, Tuck

To: scaram(o)uche who wrote (756)	1/23/2002 8:26:25 PM
From: tuck	Read Replies (3) \| Respond to of 2243

>>Ubiquitin ligases...... I don't know much about them. If there are different ligases for regulatory proteins like CDKs (take note, apostrophe police!!), then it might make sense. If not, it seems like just another anti-cancer approach that will land us in "selective toxicity" land.<< Would the results turned up by this search indicate that there are different ligases for regulatory proteins like CDKs? medscape.com Probably just showing off my ignorance, and none of this is even preclinical. But Rigel claims it will be ready to file an IND in the summer. If that's so, might not we expect publication of preclinical data pretty soon? Which might support the stock? An EDGAR search reveals no large sellers yet. Granted, they just did a cheap secondary, but getting it done at all might be a good sign. In sum, wondering if we really have that much time to decide about these folks. My Mom owns a bit, and I'm thinking of getting back in, too. Cheers, Tuck